Company No: 12470257 (England and Wales)

Contents

• Company Information
• Balance Sheet
• Notes to the Financial Statements

DIRECTORS	J W Hall (Resigned 30 October 2025)
	P Quinn (Appointed 19 December 2025)
	T L Rowe (Appointed 01 April 2025, Resigned 30 November 2025)
	B Schuler
	Rosalind Jane Sutton (Appointed 01 May 2026)
	S A Ware (Resigned 16 December 2025)

REGISTERED OFFICE	Fishleigh Court
	Fishleigh Road
	Barnstaple
	EX31 3UD
	United Kingdom

COMPANY NUMBER

12470257 (England and Wales)

AUDITOR	Gravita Audit Western Limited
	Chartered Accountants and Statutory Auditors
	Statutory Auditor
	Keble House
	Southernhay Gardens
	Exeter
	Devon
	EX1 1NT
	United Kingdom

	Note	31.12.2025		31.12.2024
		£		£
Current assets
Debtors	3	100		920
Cash at bank and in hand		442		5,764
		542		6,684
Creditors: amounts falling due within one year	4	307		( 6,218)
Net current assets		849		466
Total assets less current liabilities		849		466
Net assets		849		466
Capital and reserves
Called-up share capital		100		100
Profit and loss account		749		366
Total shareholder's funds		849		466

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Profit and Loss Account has not been delivered.

The financial statements of Taw Pharma Limited (registered number: 12470257) were approved and authorised for issue by the Board of Directors on 21 September 2026. They were signed on its behalf by:

B Schuler Director

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Taw Pharma Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Fishleigh Court, Fishleigh Road, Barnstaple, EX31 3UD, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The financial statements have been prepared on a going concern basis. Taw Pharma Ltd will soon be a dormant company with no significant financial transactions; and minimal business activities. Taw Pharma Ltd previously held regulatory approval to distribute and commercialise pharmaceutical products. We plan to make the company dormant, we are not closing the company incase of future opportunities.

Accordingly the directors still believe it is appropriate to prepare the accounts on a going concern basis.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is measured at the fair value of the consideration received for services rendered, net of discounts and Value Added Tax.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets is reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The key estimates and judgements included in the financial statements are accruals which are based on information available at the time of approval of the financial statements

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

	31.12.2025		31.12.2024
	Number		Number
Monthly average number of persons employed by the Company during the year, including directors	3		3

3. Debtors

	31.12.2025		31.12.2024
	£		£
Trade debtors	0		338
Amounts owed by Group undertakings	100		232
Prepayments	0		350
	100		920

4. Creditors: amounts falling due within one year

	31.12.2025		31.12.2024
	£		£
Trade creditors	0		1,017
Accruals	0		4,900
Taxation and social security	( 307)		301
	( 307)		6,218

5. Related party transactions

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

6. Audit Opinion

Under section 444(5B) of the Companies Act 2006, the auditor's report on the accounts for the financial year ended 31 December 2025 was unqualified.

The audit report was signed by Jade Quaintance FCA BA on behalf of Gravita Audit Western Limited, Chartered Accountants.

7. Ultimate controlling party

Parent Company:

The company is under control of Regenold UK & Ireland Holdings Ltd, it's parent company.

The registered office is Fishleigh Court, Fishleigh Road, Barnstaple, Devon, EX31 3UD.

The ultimate controlling party is Mr Jeurgen Regenold.